Biosimilar adoption is ramping up in the U.S., and biosimilars have already found wide use in Europe since they were first introduced there in 2006.  Growing biosimilar adoption, however, do more than chip away at biologics revenue — they often fuel price erosion. An IQVIA report concluded that biosimilar use in Europe enabled €5.7 billion in…